Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine the tolerance and side effects of a combination of lentinan and didanosine (ddI) in comparison with ddI alone. To determine whether the combination of lentinan and ddI produces a significant immunorestorative effect within the study observation period (6-12 months) as measured by an increase in one or more of the following: neutrophil count and activity, T-cell subsets, and a decrease in p24 antigen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AJI Pharma USA
• Treatments: Didanosine; Lentinan

Criteria

Inclusion Criteria

Patients must have:

• HIV seropositivity.

• Absolute CD4 count of 200 - 500 cells/mm3.

• No active opportunistic infection or Kaposi's sarcoma.

Prior Medication:

Allowed:

• Prior ddI for no longer than 3 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Lymphoid malignancy.

• Pancreatitis.

• Peripheral neuropathy.

• Critical illness.

Concurrent Medication:

Excluded:

• Antiretroviral agents other than ddI.

• Steroids.

• Cytotoxic agents.

• Immunosuppressive agents.

• Immunomodulators.

• 1-Thyroxine.

Concurrent Treatment:

Excluded:

• Radiotherapy.

Prior Medication:

Excluded within 1 month prior to study entry:

• Antiretroviral agents other than ddI (patients may have received prior ddI for no longer than 3 months total).

• Steroids.

• Cytotoxic agents.

• Immunosuppressive agents.

• Immunomodulators.

Prior Treatment:

Excluded:

• Radiotherapy within 1 month prior to study entry. Active IV drug abuse.